<DOC>
	<DOC>NCT01232335</DOC>
	<brief_summary>The purpose of this study is to confirm the safety profile for long term treatment and maximize doses and the control status on bronchial asthma in daily clinical usage</brief_summary>
	<brief_title>Symbicort Turbuhaler 30/60 Specific Clinical Experience Investigation</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<criteria>Patients treated with Symbicort for the first time possibly at the higher dose due to bronchial asthma</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>bronchial asthma</keyword>
	<keyword>Symbicort</keyword>
	<keyword>long term use,</keyword>
</DOC>